These genetic testing stocks took divergent paths in the final months of 2019, but they're solid options for investors with a long-term mindset.
News & Analysis: Invitae
NVTA earnings call for the period ending September 30, 2019.
Most stocks in the industry cooled off from all-time highs. Will they keep sliding?
NVTA earnings call for the period ending June 30, 2019.
It was a great month to be a genetic testing company.
Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.
These three businesses may not be household names, but someday, they could be.
Management thinks the company is on track for $500 million in revenue in 2020, but achieving that will require considerable capital investment.
Sales slipped from the fourth quarter, but there's still a lot to like about this company.
The genetic testing leader and Wall Street weren't on the same page for first-quarter 2019 revenue.